F2G CEO outlines biotech’s FDA resubmission plans, funding and expansionnews2026-01-23T16:38:10+00:00January 23rd, 2026|Endpoints News|
Sanofi’s Phase 3 eczema data cloud hopes for potential immunology blockbusternews2026-01-23T15:39:18+00:00January 23rd, 2026|Endpoints News|
Lilly was the only pharma bidder for Ventyxnews2026-01-23T12:20:13+00:00January 23rd, 2026|Endpoints News|
Insurance CEOs defend their businesses at House hearingnews2026-01-23T12:10:15+00:00January 23rd, 2026|Endpoints News|
Former FDA deputies land at Lilly, AbbVie; Italy’s Angelini has a new CEOnews2026-01-23T12:00:32+00:00January 23rd, 2026|Endpoints News|
High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’ news2026-01-22T19:53:16+00:00January 22nd, 2026|Endpoints News|
Drugmakers spent less on Washington lobbying in 2025’s final quarternews2026-01-22T18:35:32+00:00January 22nd, 2026|Endpoints News|
Corcept’s drug extends patients’ lives in key ovarian cancer studynews2026-01-22T16:08:57+00:00January 22nd, 2026|Endpoints News|
China-founded pharma Corxel raises up to $287M for oral GLP-1news2026-01-22T16:00:43+00:00January 22nd, 2026|Endpoints News|
